Please login to the form below

Not currently logged in
Email:
Password:

EMEA demands updated Champix warnings

The EMEA asks Pfizer to include a warning on its smoking cessation product Champix over the high risk of suicide attempts among patients taking the drug

The European Medicines Agency (EMEA) has asked US-based pharmaceutical company Pfizer to include a warning on its smoking cessation product Champix (varenicline), regarding the high risk of suicide attempts among patients taking the drug.

In November 2007, the FDA released an "early communication", which warned of reports of erratic behaviour in patients prescribed Chantix, as it is known in the US. An early communication represents a review and analysis of available data.

Pfizer submitted reports to the FDA describing suicidal thoughts and erratic behaviour in one person who had used the drug, along with at least one other possibly linked death.

The FDA conceded that other factors, including alcohol consumption, appear to have had an impact in this specific case, and the agency asked Pfizer for additional similar cases.

In the EU, Champix, which was first authorised in September 2006 and has been closely monitored by The Committee for Medicinal Products for Human Use (CHMP) regularly as part of routine pharmacovigilance analyses. Cases of suicidal ideation and suicide were reviewed in July, October and November 2007.

At its December 2007 meeting, the CHMP said that Pfizer needed to update the product information to warn doctors and patients that depression has been reported among patients using Champix. The depression may further lead to suicidal thoughts and attempts.

The CHMP has asked Pfizer to submit a variation to the marketing authorisation for Champix before 19 December 2007 to implement these changes to the product information.

Pfizer said there was no scientific evidence that connected Champix to the reported events. It added that it was working closely with the EMEA to review individual case histories.

The labelling update on Champix led to a fall in shares of Pfizer on the 14 December. In Q3 FY07, the drug racked up sales of USD 241m.

17th December 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics